Hematology Reports
Scope & Guideline
Connecting ideas to improve patient outcomes.
Introduction
Aims and Scopes
- Clinical Hematology:
The journal emphasizes clinical research that explores the diagnosis, treatment, and management of hematological conditions, including various anemias, leukemias, lymphomas, and bleeding disorders. - Translational Research:
It publishes studies that bridge laboratory findings and clinical applications, aiming to enhance understanding of hematological diseases and improve therapeutic strategies. - Case Reports and Reviews:
The journal features detailed case reports and comprehensive reviews that contribute to clinical knowledge, providing insights into rare and complex hematological conditions. - Innovative Therapies:
A focus on novel therapeutic approaches, including targeted therapies, immunotherapies, and combination treatments, reflecting the evolving landscape of hematologic treatments. - Epidemiology and Outcomes Research:
Research addressing the epidemiology, risk factors, and outcomes associated with different hematological disorders, contributing to evidence-based practice in hematology.
Trending and Emerging
- COVID-19 and Hematology:
A significant focus on the impact of COVID-19 on hematological patients, including complications, management strategies, and vaccine responses, showcasing the pandemic's influence on research priorities. - Immunotherapy and Targeted Treatments:
An increasing number of studies are dedicated to the exploration of immunotherapy and targeted therapies, such as CAR-T cell therapy and novel agents for hematological malignancies. - Real-World Evidence and Clinical Outcomes:
Emerging interest in real-world data studies that assess treatment patterns and outcomes in diverse patient populations, providing insights into the effectiveness of therapies in practice. - Genomic and Molecular Characterization:
There is a growing trend towards the genomic and molecular profiling of hematological diseases, enhancing personalized medicine approaches and treatment decisions. - Quality of Life and Patient-Centered Research:
Increased emphasis on research assessing quality of life and patient-reported outcomes in hematology, recognizing the importance of holistic patient care.
Declining or Waning
- Traditional Chemotherapy Approaches:
There is a noticeable decrease in studies solely focused on traditional chemotherapy regimens for hematological malignancies, as newer targeted therapies and immunotherapies gain prominence. - Longitudinal Studies on Established Treatments:
Research centered on long-term outcomes of established treatments, like older chemotherapy agents, has diminished, suggesting a shift towards exploring novel and combination therapies. - Basic Science Studies:
The journal has seen fewer publications centered on basic science without direct clinical applications, reflecting a trend towards more clinically relevant and translational research.
Similar Journals
Blood and Lymphatic Cancer-Targets and Therapy
Bridging Research and Practice in HematologyBlood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.
Turkish Journal of Hematology
Empowering the global hematology community through open access.Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.
INTERNATIONAL JOURNAL OF HEMATOLOGY
Pioneering Discoveries in Hematological ScienceThe INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.
Hematology Transfusion and Cell Therapy
Elevating standards in cell therapy and transfusion science.Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.
Journal of Blood Medicine
Empowering Research: Your Gateway to Innovations in HematologyThe Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.
Plasmatology
Elevating the Discourse in HematologyPlasmatology, published by SAGE Publications Ltd, is a pioneering open-access journal devoted to the field of hematology, focusing on the latest advancements and research in plasma science and its applications. Established in 2021, this journal aims to foster knowledge exchange among researchers, practitioners, and students by providing a platform for sharing innovative studies and reviews. While currently positioned in the Q4 quartile for hematology and ranking #111 in the Scopus database, Plasmatology is dedicated to enhancing its influence and reflecting the dynamic nature of hematological research. With access options freely available to all, the journal encourages a collaborative approach to address the challenges and developments in the field. Based in the United Kingdom, Plasmatology is an emerging resource for anyone interested in advancing their understanding and involvement in plasma research.
GEMATOLOGIYA I TRANSFUZIOLOGIYA
Bridging Research and Practice in HematologyGEMATOLOGIYA I TRANSFUZIOLOGIYA is an esteemed journal published by the MINISTERSTVO ZDRAVOOKHRANENIYA in the Russian Federation, focusing on the vital fields of hematology and transfusion medicine. With a rich history dating back to its inception in 1983, the journal plays a significant role in disseminating critical research and advancements in these areas, particularly relevant given the evolving landscape of medical science. As a recognized publication, it is indexed in Scopus and holds a Q4 category ranking in Hematology for 2023, reflecting its niche but important contributions to the field. Researchers, healthcare professionals, and students can look forward to a variety of peer-reviewed articles that not only address contemporary issues but also pave the way for innovative practices in hematology. Although it does not currently offer open access, the journal remains a valuable resource for those seeking to stay informed about the latest findings and developments.
ANNALS OF CLINICAL AND LABORATORY SCIENCE
Fostering Collaboration in Clinical ResearchANNALS OF CLINICAL AND LABORATORY SCIENCE, published by the Association of Clinical Scientists, is a pivotal journal in the fields of clinical biochemistry, hematology, immunology, and medical laboratory technology. Since its inception in 1971, this journal has become a vital resource for researchers and practitioners aiming to advance their knowledge and skills in laboratory sciences. Although currently not an open access journal, its rich repository of peer-reviewed articles and studies contributes significantly to the academic discourse in diagnostic and therapeutic practices. The journal is categorized in various quartiles, reflecting its impact and contributions to multiple scientific domains, such as Q4 in Clinical Biochemistry and Q3 in Pathology and Forensic Medicine as of 2023. With an extensive convergence of years up to 2024, it proves to be a timeless source for emerging trends and research innovations. The ANNALS OF CLINICAL AND LABORATORY SCIENCE not only supports the professional development of its readers but also encourages interdisciplinary collaboration, making it an essential tool for professionals, students, and researchers dedicated to improving health outcomes through advanced laboratory sciences.
Hematology-American Society of Hematology Education Program
Fostering Excellence in Hematological ResearchHematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.
Hematologie
Driving Clinical Practice with Cutting-Edge ResearchHematologie is a highly regarded journal in the field of hematology, published by JOHN LIBBEY EUROTEXT LTD. With an ISSN of 1264-7527 and an E-ISSN of 1950-6368, this journal has established itself as a vital resource for researchers, clinicians, and students dedicated to advancing the understanding of blood disorders and treatments. Although the journal's coverage in Scopus was discontinued in 2018, it has continually provided invaluable insights and research findings. The journal aims to foster knowledge sharing and discussion in hematology, exploring innovative methodologies and emerging trends in the field. With a commitment to quality research, Hematologie remains an essential platform for disseminating critical findings that can drive clinical practice and influence future studies in hematological sciences.